Inactive Instrument

Lansen Pharmaceutical Holdings Limited Stock price

Equities

503

KYG5380M1033

Pharmaceuticals

Dynamic Chart
Lansen Pharmaceutical to Delist from HKEX on Dec. 19 MT
Cayman Islands Court Approves Takeover, Privatization of Lansen Pharma MT
Cathay International Holdings Limited completed the acquisition of additional 31.78% stake in Lansen Pharmaceutical Holdings Limited. CI
Cathay International Pharma to Privatize Lansen Pharmaceutical in HK$239 Million Deal MT
Lansen Pharmaceutical's H1 Profit Slides 17% MT
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lansen Pharmaceutical Holdings Limited commences an Equity Buyback Plan for 42,243,243 shares, representing 10% of its issued share capital, under the authorization approved on June 21, 2023. CI
Lansen Pharmaceutical Holdings Limited's Equity Buyback announced on June 24, 2022, has expired. CI
Tranche Update on Lansen Pharmaceutical Holdings Limited's Equity Buyback Plan announced on June 24, 2022. CI
Lansen Pharmaceutical Holdings Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Lansen Pharmaceutical Holdings Limited Declares Interim Dividend CI
Lansen Pharmaceutical Expects 2022 Profit Soaring 798%; Shares Surge 22% MT
Lansen Pharmaceutical Holdings Limited Provides Earnings Guidance for the Twelve Months Ended 31 December 2022 CI
Lansen Pharmaceutical Holdings Limited Appoints Zhu Xun as Independent Non-Executive Director and Member of the Remuneration Committee CI
Tranche Update on Lansen Pharmaceutical Holdings Limited's Equity Buyback Plan announced on June 24, 2022. CI
More news
Managers TitleAgeSince
Chief Executive Officer 62 18-02-28
Corporate Secretary - 19-06-12
Human Resources Officer 51 15-12-10
Members of the board TitleAgeSince
Director/Board Member 67 22-02-09
Chairman 70 17-03-29
Director/Board Member 72 10-04-08
More insiders
Lansen Pharmaceutical Holdings Limited is a Hong Kong-based investment holding company principally engaged in pharmaceutical businesses. The Company operates through three segments. Specialty Pharmaceuticals segment is engaged in the development, production and sales of specialty pharmaceuticals mainly used in the fields of rheumatology and dermatology. Its main specialty pharmaceutical products include pafulin, leflunomide tablets and mycophenolate mofetil dispersible tablets. Plant Extract and Healthcare Products segment is engaged in the development, production and sales of Chinese medicine extracts and healthcare products. Other Pharmaceuticals segment is engaged in businesses related to other pharmaceuticals.
More about the company
  1. Stock
  2. Equities
  3. Stock Lansen Pharmaceutical Holdings Limited - Hong Kong S.E.